A Wall Street analyst has provided a review for the Healthcare company today, but retained the same rating on the stock. The Healthcare company, BriaCell Therapeutics (TSX: BCT) has just received a rating update from a Wall Street analyst.
According to TipRanks.com, Bodnar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -15.9% and a 24.6% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Gracell Biotechnologies, and TransCode Therapeutics.
BriaCell Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of C$24.87.
Based on BriaCell Therapeutics’ latest earnings release for the quarter ending April 30, the company reported a quarterly net profit of C$0. In comparison, last year the company had a net profit of C$0.
BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.
The company’s shares closed last Thursday at C$6.02, close to its 52-week low of C$5.70.
Read More on TSE:BCT:
- BriaCell forms medical advisory board
- BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate
- October is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative Technology
- BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences
- BriaCell To Host Virtual Key Opinion Leader Event on Bria-IMT™ Potential in Advanced Metastatic Breast Cancer on October 26, 2023 Featuring Dr. Adam M. Brufsky from University of Pittsburgh School of Medicine and Dr. Saranya Chumsri from Mayo Clinic
